06-26-06

Please type a plus sign (+) inside this box Π

+

PTO/SB/21 (6-99)
Approved for use through 09/30/2000. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

		Application Number			10/617,292					
IPE WIR	ANSMITTA	Filing Date			September 24, 2003					
FORM (to be used for all correspondence after initial filing)			First Named Inventor			Roland Buelow et al.				
			Group/Art Unit			1632				
1 TRADEMARKO			Examiner Name			Unassigned				
Total Number of I	Pages in This Submission	Attorney Docket	Number		39691-0012A					
ENCLOSURES (check all that apply)										
Incomplete Application Response to Missing AUTI DOC		Contact Cont	LIZATION TO CHARGE DEPOSIT NO.: 39691-0012A) FOR ANY FE			After Allowance Communication to Group Appeal Communication to Board of Appeals and Interferences Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) Status Letter Additional Enclosure(s) (please identify below): COPY OF EP SEARCH REPORT AND STAMPED RETURN POSTCARD				
	SIGNA	ATURE OF APP	LICANT, ATTORN	EY OR AC	GENT					
Firm or Individual name	Daphne Reddy, Reg. No	o. 53,507, HELLE	R EHRMAN LLP							
Signature	Kaphne Red	dy				·				
Date	J June 22, 2006	0	Customer Numb	per: 252	213					
		CERTIFICAT	E OF EXPRESS MA	AILING	-					
I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated below and addressed to: Mail Stop: xxxxxx; Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 Express Mail Label: EV 765 972 931 US										
Typed or printed r	name Elena Torres		Express Wall La	OCI. EV A	,,,,,,,	231 00				
Signature	Mina	100	7	Date	June 2	22, 2006				

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop ____, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

CERTIFICATE OF EXPRESS MAILING I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated below and addressed to: Mail Stop: Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA on the date indicated below. Express Mail Label: EV 765 972 931 US Typed or print name Elega Torres Date ignature Attorney Docket No.: 39691-0012A

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT

PATENT APPLICATION Inventor(s): Roland Buelow et al. Art Unit: 1632 Application No.: 10/617,292 Examiner: Unassigned Filed: September 24, 2003 Title: HUMANIZED IMMUNOGLOBULIN

INFORMATION DISCLOSURE STATEMENT

UNDER 37 C.F.R. §1.97

Mail Stop: AMENDMENT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

PREPARATION

Sir:

Listed below or on an attached Form PTO-1449 is information known to applicant(s). A copy is provided of each foreign patent, each cited pending unpublished U.S. application, and all additional publications other than U.S. patents and U.S. patent application publications. 37 C.F.R. §§1.97-1.98.

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. If form PTO-1449 is enclosed, the Examiner is requested to initial and return it in accordance with MPEP §609.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56.

\boxtimes	This sta	atement	qualifies under 37 C.F.R. §1.97,	subsection (b) because (check all that apply):							
		(1)	It is being filed within 3 months prosecution application under §	of the application filing date and is other than a continued 1.53(d)							
		(2)	It is being filed within 3 months	s of entry of a national stage							
	\boxtimes	(3)		date of the first Office Action on the merits							
		(4)		ng of a first Office Action after the filing of a request for 1.114.							
	of a nat §1.491	tional ar in an in the mail	oplication; (2) three months beyon ternational application; or (3) the	ed after the latest of: (1) three months beyond the filing date of the date of entry of the national stage as set forth in mailing date of a first Office action on the merits, but ffice action under §1.113 or a notice of allowance under							
		a certif	fication as specified in §1.97(e) is	provided below; or							
			fee of \$180.00 as set forth in \$1.17(p) is authorized below, enclosed, or included with the syment of other papers filed together with this statement.								
	37 C.F.R. §1.97(d). If this statement is being filed after the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, but before payment of the issue fee, then:										
	A.	a certif	fication as specified in §1.97(e) is	completed below; and							
	B. a petition under 37 C.F.R. §1.97(d) requesting consideration of this statement is submitted herewith; and										
	C.	a fee of \$130.00 as set forth in §1.17(i)(1) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.									
\boxtimes	Fee Authorization. The Commissioner is hereby authorized to charge the above-referenced fees and charge any additional fees or credit any overpayment associated with this communication to Deposit Account No. 08-1641 (Docket No.: 39691-0012A).										
				Respectfully submitted,							
				HELLER EHRMAN LLP							
Dated:	6	122/0	06	By: Daphne Reddy							
HELLI	ER EHR	MAN L	LP	Reg. No.: 53,507							
000 1 1	1 11 6 1	1 D 1									

HELLER EHRMAN LLP 275 Middlefield Road Menlo Park, CA 94025-3506 Telephone: 1.650.324.7115 Facsimile: 1.650.324.0638

Customer No.: 25213

										1 01 1		
INFORMATION DISCLOSURE				ATTY	DOCKET NO.	SERIAL NO.						
O F STATEMENT				39691-0012A 10/671,292								
JUN ? 2 2006 PTO-1449			APPLI	APPLICANT: Roland Buelow et al.								
			FILIN	G DATE: 09/24/2003	GROUP: 1632							
EXAMINER'S INITIALS	PATENT NO.		DAT			CLASS SUBCLASS		FILING DATE				
	,		_									
									<u></u>			
		F	FOR	EIGN P	ATENT DOCUMENTS	1		-·				
EXAMINER'S INITIALS	PATENT NO.		DAT	E	COUNTRY	CLA	LASS	SUBCLASS	TRANS YES	NO		
	92/03918	199	92-03-19		wo					П		
					wo							
	OZ/12437 2002-02-14 WO L L CONTROLL CON											
	Bruggemann, M et al., "A Repertoire of Monoclonal Antibodies with Human Heavy Chains from Transgenic Mice", Proceedings of the National Academy of Sciences of USA, National Academy of Science. Washington, US, vol. 86, no. 17; pp. 6709-6713 (1989) XP000068417. Brueggeman, M et al., "Stragegies for Expressing Human Antibody Repertoires in Transgenic Mice", Immunology Today, Elsevier Publications, Cambridge, GB, vol. 17, no. 8, pp.391-397 (1996)											
,	 XP002067729. Jakobovitz, A et al., "Analysis of Homozygous Mutant Chimeric Mice: Deletion of the Immunoglobulin Heavy-Chain Joining Region Blocks B-Cell developmentand Antibody Production", Proceedings of the National Academy of Science of USA, National Academy of Science. Washington, USA, vol. 90, no. 6, pp. 2551-2555 (1993) XP000673147. Ros, F et al., "Sequence Analysis of 0.5 Mb of the Rabbit Germline Immunoglobulin Heavy Chain Locus" 											
	Gene: An International Journal on Genes and Genomes, Elsevier Science Publishers, Barking, GB, vol. 330, pp. 49-59 (2004) XP004503493.											
-												
		•										
		· ·					•		· · · -			
1						<u>.</u>	·					
•			<u> </u>	•								
EYAMINER				DAT	F CONSIDERED							

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.